Progyny (PGNY) Expected to Post Quarterly Earnings on Thursday

Progyny (NASDAQ:PGNY) is expected to be posting its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Progyny to announce earnings of $0.3348 per share and revenue of $348.6260 million for the quarter. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Interested persons may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:45 PM ET.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.24. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The firm had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.46 million. During the same period last year, the firm posted $0.17 earnings per share. The business’s revenue for the quarter was down 26.4% on a year-over-year basis. On average, analysts expect Progyny to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Progyny Stock Performance

Shares of Progyny stock traded down $0.08 on Tuesday, hitting $31.45. The stock had a trading volume of 86,388 shares, compared to its average volume of 1,463,651. The stock has a 50 day moving average of $28.69 and a 200 day moving average of $23.27. The firm has a market capitalization of $2.46 billion, a P/E ratio of 40.84, a PEG ratio of 2.47 and a beta of 1.01. Progyny has a twelve month low of $16.10 and a twelve month high of $33.06.

Progyny announced that its board has approved a stock repurchase program on Tuesday, May 26th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 10.3% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In other news, CFO Mark S. Livingston sold 8,275 shares of Progyny stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $25.50, for a total value of $211,012.50. Following the completion of the transaction, the chief financial officer directly owned 79,063 shares of the company’s stock, valued at approximately $2,016,106.50. This trade represents a 9.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Geoffrey Clapp sold 1,530 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $25.58, for a total value of $39,137.40. Following the completion of the transaction, the insider directly owned 59,117 shares in the company, valued at $1,512,212.86. This represents a 2.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 36,916 shares of company stock valued at $939,875 over the last quarter. Company insiders own 9.90% of the company’s stock.

Hedge Funds Weigh In On Progyny

Institutional investors and hedge funds have recently made changes to their positions in the stock. Occudo Quantitative Strategies LP bought a new position in shares of Progyny in the 4th quarter worth $264,000. Inceptionr LLC acquired a new stake in Progyny in the 4th quarter valued at $229,000. iSAM Funds UK Ltd acquired a new stake in Progyny in the 3rd quarter valued at $251,000. Aristides Capital LLC increased its stake in Progyny by 4.6% during the 3rd quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock valued at $257,000 after purchasing an additional 528 shares in the last quarter. Finally, Teza Capital Management LLC increased its stake in Progyny by 5.4% during the 2nd quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock valued at $221,000 after purchasing an additional 516 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on PGNY. Weiss Ratings upgraded shares of Progyny from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, June 26th. Zacks Research raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 8th. BTIG Research increased their price objective on Progyny from $30.00 to $40.00 and gave the company a “buy” rating in a report on Friday, July 24th. Citizens Jmp raised their target price on Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a research report on Monday, May 11th. Finally, Wall Street Zen downgraded Progyny from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Progyny currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.25.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.